{
  "section": "objectives_endpoints",
  "rating": "GREAT",
  "status": "pass",
  "extraction": {
    "original_sap": [
      {
        "component": "Primary Objective",
        "type": "objective",
        "text": "To demonstrate CT-P16 is similar to EU-Approved Avastin in terms of efficacy as determined by objective response rate (ORR) during the Induction Study Period"
      },
      {
        "component": "Secondary Objective",
        "type": "objective",
        "text": "To evaluate additional efficacy profiles including ORR during the Whole Study Period, response duration, time to progression (TTP), progression-free survival (PFS), and overall survival (OS)"
      },
      {
        "component": "Secondary Objective",
        "type": "objective",
        "text": "To evaluate the Pharmacokinetic (PK) parameter of trough serum concentration (Ctrough)"
      },
      {
        "component": "Secondary Objective",
        "type": "objective",
        "text": "To evaluate safety profile including immunogenicity"
      },
      {
        "component": "Secondary Objective",
        "type": "objective",
        "text": "To evaluate quality of life (QoL)"
      },
      {
        "component": "Primary Efficacy Endpoint",
        "type": "endpoint",
        "text": "ORR based on BOR during the Induction Study Period by RECIST version 1.1"
      },
      {
        "component": "Secondary Efficacy Endpoint",
        "type": "endpoint",
        "text": "Objective Response Rate during the Whole Study Period"
      },
      {
        "component": "Secondary Efficacy Endpoint",
        "type": "endpoint",
        "text": "Response Duration"
      },
      {
        "component": "Secondary Efficacy Endpoint",
        "type": "endpoint",
        "text": "Time to Progression"
      },
      {
        "component": "Secondary Efficacy Endpoint",
        "type": "endpoint",
        "text": "Progression-free Survival"
      },
      {
        "component": "Secondary Efficacy Endpoint",
        "type": "endpoint",
        "text": "Overall Survival"
      },
      {
        "component": "PK Endpoint",
        "type": "endpoint",
        "text": "trough serum concentration (Ctrough)"
      },
      {
        "component": "Safety Endpoint",
        "type": "endpoint",
        "text": "Adverse Events"
      },
      {
        "component": "Safety Endpoint",
        "type": "endpoint",
        "text": "Clinical Laboratory Evaluations"
      },
      {
        "component": "Safety Endpoint",
        "type": "endpoint",
        "text": "Vital Signs, Weight and Body Surface Area"
      },
      {
        "component": "Safety Endpoint",
        "type": "endpoint",
        "text": "Electrocardiograms"
      },
      {
        "component": "Safety Endpoint",
        "type": "endpoint",
        "text": "Hypersensitivity Monitoring"
      },
      {
        "component": "Safety Endpoint",
        "type": "endpoint",
        "text": "Physical Examination"
      },
      {
        "component": "Safety Endpoint",
        "type": "endpoint",
        "text": "Pregnancy Test"
      },
      {
        "component": "Safety Endpoint",
        "type": "endpoint",
        "text": "ECOG Performance Status"
      },
      {
        "component": "Safety Endpoint",
        "type": "endpoint",
        "text": "Immunogenicity"
      },
      {
        "component": "QoL Endpoint",
        "type": "endpoint",
        "text": "EORTC QLQ"
      }
    ],
    "generated_sap": [
      {
        "component": "Primary Objective",
        "type": "objective",
        "text": "To demonstrate CT-P16 is similar to EU-Approved Avastin in terms of efficacy as determined by objective response rate (ORR) up to Cycle 6 during the Induction Study Period"
      },
      {
        "component": "Secondary Objective",
        "type": "objective",
        "text": "To evaluate additional efficacy profiles including ORR during the Whole Study Period, response duration, time to progression (TTP), progression-free survival (PFS), and overall survival (OS)"
      },
      {
        "component": "Secondary Objective",
        "type": "objective",
        "text": "To evaluate the pharmacokinetics (PK) of trough serum concentration (Ctrough)"
      },
      {
        "component": "Secondary Objective",
        "type": "objective",
        "text": "To evaluate safety profile including immunogenicity"
      },
      {
        "component": "Secondary Objective",
        "type": "objective",
        "text": "To evaluate quality of life (QoL)"
      },
      {
        "component": "Primary Endpoint",
        "type": "endpoint",
        "text": "Objective response rate (ORR, %) based on BOR during the Induction Study Period by RECIST v.1.1"
      },
      {
        "component": "Secondary Efficacy Endpoint",
        "type": "endpoint",
        "text": "ORR based on BOR during the Whole Study Period by RECIST v.1.1"
      },
      {
        "component": "Secondary Efficacy Endpoint",
        "type": "endpoint",
        "text": "Response duration"
      },
      {
        "component": "Secondary Efficacy Endpoint",
        "type": "endpoint",
        "text": "TTP"
      },
      {
        "component": "Secondary Efficacy Endpoint",
        "type": "endpoint",
        "text": "PFS"
      },
      {
        "component": "Secondary Efficacy Endpoint",
        "type": "endpoint",
        "text": "OS"
      },
      {
        "component": "PK Endpoint",
        "type": "endpoint",
        "text": "Ctrough: Trough serum concentration"
      },
      {
        "component": "QoL Endpoint",
        "type": "endpoint",
        "text": "QLQ-C30 and QLQ-LC13, using EORTC QLQ"
      },
      {
        "component": "Safety Endpoint",
        "type": "endpoint",
        "text": "Incidence and severity of AEs, including SAEs graded according to the NCI CTCAE v.5.0."
      },
      {
        "component": "Safety Endpoint",
        "type": "endpoint",
        "text": "Incidence and severity of AESIs graded according to the NCI CTCAE v.5.0."
      },
      {
        "component": "Safety Endpoint",
        "type": "endpoint",
        "text": "Immunogenicity, as assessed by the incidence of antidrug antibody and neutralized antidrug antibody."
      },
      {
        "component": "Safety Endpoint",
        "type": "endpoint",
        "text": "Vital sign measurements"
      },
      {
        "component": "Safety Endpoint",
        "type": "endpoint",
        "text": "ECG"
      },
      {
        "component": "Safety Endpoint",
        "type": "endpoint",
        "text": "Physical examination findings"
      },
      {
        "component": "Safety Endpoint",
        "type": "endpoint",
        "text": "ECOG"
      },
      {
        "component": "Safety Endpoint",
        "type": "endpoint",
        "text": "Pregnancy testing"
      },
      {
        "component": "Safety Endpoint",
        "type": "endpoint",
        "text": "Clinical laboratory analyses"
      },
      {
        "component": "Safety Endpoint",
        "type": "endpoint",
        "text": "Previous and concomitant medications"
      }
    ],
    "protocol": [
      {
        "component": "Primary Objective",
        "type": "objective",
        "text": "To demonstrate CT-P16 is similar to EU-Approved Avastin in terms of efficacy as determined by objective response rate (ORR) up to Cycle 6 during the Induction Study Period"
      },
      {
        "component": "Secondary Objective",
        "type": "objective",
        "text": "To evaluate additional efficacy profiles including ORR during the Whole Study Period, response duration, time to progression (TTP), PFS, and OS"
      },
      {
        "component": "Secondary Objective",
        "type": "objective",
        "text": "To evaluate the PK of trough serum concentration (Ctrough)"
      },
      {
        "component": "Secondary Objective",
        "type": "objective",
        "text": "To evaluate safety profile including immunogenicity"
      },
      {
        "component": "Secondary Objective",
        "type": "objective",
        "text": "To evaluate quality of life (QoL)"
      },
      {
        "component": "Primary Endpoint",
        "type": "endpoint",
        "text": "Objective response rate (ORR, %) based on BOR during the Induction Study Period by RECIST v.1.1"
      },
      {
        "component": "Secondary Efficacy Endpoint",
        "type": "endpoint",
        "text": "ORR based on BOR during the Whole Study Period by RECIST v.1.1"
      },
      {
        "component": "Secondary Efficacy Endpoint",
        "type": "endpoint",
        "text": "Response duration"
      },
      {
        "component": "Secondary Efficacy Endpoint",
        "type": "endpoint",
        "text": "TTP"
      },
      {
        "component": "Secondary Efficacy Endpoint",
        "type": "endpoint",
        "text": "PFS"
      },
      {
        "component": "Secondary Efficacy Endpoint",
        "type": "endpoint",
        "text": "OS"
      },
      {
        "component": "PK Endpoint",
        "type": "endpoint",
        "text": "trough serum concentration (Ctrough)"
      },
      {
        "component": "QoL Endpoint",
        "type": "endpoint",
        "text": "QLQ-C30 and QLQ-LC13, using EORTC QLQ"
      },
      {
        "component": "Safety Endpoint",
        "type": "endpoint",
        "text": "Incidence and severity of AEs, including SAEs graded according to the NCI CTCAE v.5.0."
      },
      {
        "component": "Safety Endpoint",
        "type": "endpoint",
        "text": "Incidence and severity of AESIs graded according to the NCI CTCAE v.5.0."
      },
      {
        "component": "Safety Endpoint",
        "type": "endpoint",
        "text": "Immunogenicity, as assessed by the incidence of antidrug antibody and neutralized antidrug antibody."
      },
      {
        "component": "Safety Endpoint",
        "type": "endpoint",
        "text": "Vital sign measurements"
      },
      {
        "component": "Safety Endpoint",
        "type": "endpoint",
        "text": "ECG"
      },
      {
        "component": "Safety Endpoint",
        "type": "endpoint",
        "text": "Physical examination findings"
      },
      {
        "component": "Safety Endpoint",
        "type": "endpoint",
        "text": "ECOG"
      },
      {
        "component": "Safety Endpoint",
        "type": "endpoint",
        "text": "Pregnancy testing"
      },
      {
        "component": "Safety Endpoint",
        "type": "endpoint",
        "text": "Clinical laboratory analyses"
      },
      {
        "component": "Safety Endpoint",
        "type": "endpoint",
        "text": "Previous and concomitant medications"
      }
    ]
  },
  "evaluation_table": [
    {
      "component": "Primary Objective",
      "type": "objective",
      "original_sap_text": "To demonstrate CT-P16 is similar to EU-Approved Avastin in terms of efficacy as determined by objective response rate (ORR) during the Induction Study Period",
      "generated_sap_text": "To demonstrate CT-P16 is similar to EU-Approved Avastin in terms of efficacy as determined by objective response rate (ORR) up to Cycle 6 during the Induction Study Period",
      "protocol_text": "To demonstrate CT-P16 is similar to EU-Approved Avastin in terms of efficacy as determined by objective response rate (ORR) up to Cycle 6 during the Induction Study Period",
      "matches_original_sap": "yes",
      "result": "correct",
      "reasoning": "The Generated SAP matches the Protocol exactly, which includes the specific detail 'up to Cycle 6' that was implicit in the Original SAP."
    },
    {
      "component": "Secondary Objectives",
      "type": "objective",
      "original_sap_text": "To evaluate additional efficacy profiles... PK... safety... QoL",
      "generated_sap_text": "To evaluate additional efficacy profiles... PK... safety... QoL",
      "protocol_text": "To evaluate additional efficacy profiles... PK... safety... QoL",
      "matches_original_sap": "yes",
      "result": "correct",
      "reasoning": "All secondary objectives (Efficacy, PK, Safety, QoL) are present and match."
    },
    {
      "component": "Primary Endpoint",
      "type": "endpoint",
      "original_sap_text": "ORR based on BOR during the Induction Study Period by RECIST version 1.1",
      "generated_sap_text": "Objective response rate (ORR, %) based on BOR during the Induction Study Period by RECIST v.1.1",
      "protocol_text": "Objective response rate (ORR, %) based on BOR during the Induction Study Period by RECIST v.1.1",
      "matches_original_sap": "yes",
      "result": "correct",
      "reasoning": "Matches exactly."
    },
    {
      "component": "Secondary Efficacy Endpoints",
      "type": "endpoint",
      "original_sap_text": "ORR Whole Study Period, Response Duration, TTP, PFS, OS",
      "generated_sap_text": "ORR Whole Study Period, Response Duration, TTP, PFS, OS",
      "protocol_text": "ORR Whole Study Period, Response Duration, TTP, PFS, OS",
      "matches_original_sap": "yes",
      "result": "correct",
      "reasoning": "All secondary efficacy endpoints are present."
    },
    {
      "component": "Safety Endpoints",
      "type": "endpoint",
      "original_sap_text": "Adverse Events, Clinical Laboratory Evaluations, Vital Signs..., ECG, Hypersensitivity Monitoring, Physical Examination, Pregnancy Test, ECOG, Immunogenicity",
      "generated_sap_text": "Incidence and severity of AEs... AESIs... Immunogenicity... Vital sign measurements... ECG... Physical examination... ECOG... Pregnancy testing... Clinical laboratory analyses... Previous and concomitant medications",
      "protocol_text": "Incidence and severity of AEs... AESIs... Immunogenicity... Vital sign measurements... ECG... Physical examination... ECOG... Pregnancy testing... Clinical laboratory analyses... Previous and concomitant medications",
      "matches_original_sap": "yes",
      "result": "correct",
      "reasoning": "The Generated SAP lists safety endpoints exactly as they appear in the Protocol (Section 7.2.4). This covers all items in the Original SAP's safety analysis section (Section 10), with 'Hypersensitivity' covered under 'AESIs' and 'Medications' explicitly listed as an endpoint."
    }
  ],
  "missing_from_generated_sap": [],
  "contradictions": [],
  "extra_in_generated_sap": [],
  "reasoning": "The Generated SAP accurately captures all objectives and endpoints. It aligns perfectly with the Protocol text, which is the source of truth, even where the Original SAP had minor variations in wording (e.g., adding 'up to Cycle 6' to the primary objective). Safety endpoints are listed according to the Protocol's specific list rather than the Original SAP's section headers, which is a correct approach as it captures the same data requirements.",
  "summary": "The Generated SAP successfully lists all required objectives and endpoints. It adheres strictly to the Protocol definitions, ensuring accuracy and completeness.",
  "reconciliation": {
    "performed": true,
    "missing_items_checked": 0,
    "missing_items_removed": 0,
    "removed_items": [],
    "evaluation_problems_checked": 0,
    "evaluation_problems_fixed": 0,
    "fixed_evaluation_items": []
  }
}